DeLorean Artificial Intelligence, a Miami, FL-based AI technology development company, raised $7.55M in Series A funding.
The round, which brought the total amount to approx. $11M, was led by Sopris Venture Capital, with participation from Pinta Capital Parnters, and James Chow.
The company intends to use the funds to accelerate the expansion and adoption of its Medical AI product in the USA, in Europe, the Middle East and Latin & South America.
Led by CEO and Founder Dr. MacLaughlin, DeLorean.AI builds sentient and semi-sentient systems of intelligence to address business and economic challenges for Fortune 500 companies. The company has built Medical AI, an artificial intelligence product that offers a predictive and proactive approach to treatment by creating mathematical profiles of patient journeys and treatment methodologies.
In addition to Medical AI solution, DeLorean AI holds patent-pending rights to several proprietary AI capabilities, including CPG Sales AI, Service Ticket Analysis (Ticket Analysis Prediction Engine AI – TAPE AI, Customer Relations Management AI (CRM AI), among others.
CRM AI, DeLorean AI’s first patented product, can predict the winnability of a deal in addition to the financial impacts of deals on revenue generation and costs. It works with any CRM platform, and its ability to analyze structured or unstructured data to guide business decisions has led to an in sales for clients.
